Lifecore Biomedical, Inc. - Common Stock (LFCR)
8.5800
-0.0100 (-0.12%)
NASDAQ · Last Trade: Jan 25th, 7:44 AM EST
PHILADELPHIA, Jan. 23, 2026 (GLOBE NEWSWIRE) --
By Grabar Law Office · Via GlobeNewswire · January 23, 2026
PHILADELPHIA, Jan. 22, 2026 (GLOBE NEWSWIRE) --
By Grabar Law Office · Via GlobeNewswire · January 22, 2026
PHILADELPHIA, Jan. 21, 2026 (GLOBE NEWSWIRE) --
By Grabar Law Office · Via GlobeNewswire · January 21, 2026
PHILADELPHIA, Jan. 19, 2026 (GLOBE NEWSWIRE) --
By Grabar Law Office · Via GlobeNewswire · January 19, 2026
PHILADELPHIA, Jan. 16, 2026 (GLOBE NEWSWIRE) --
By Grabar Law Office · Via GlobeNewswire · January 16, 2026
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Lifecore Biomedical, Inc. (NASDAQ: LFCR) breached their fiduciary duties to shareholders.
By Halper Sadeh LLC · Via Business Wire · January 15, 2026
PHILADELPHIA, Jan. 14, 2026 (GLOBE NEWSWIRE) --
By Grabar Law Office · Via GlobeNewswire · January 14, 2026
PHILADELPHIA, Jan. 12, 2026 (GLOBE NEWSWIRE) --
By Grabar Law Office · Via GlobeNewswire · January 12, 2026
PHILADELPHIA, Jan. 09, 2026 (GLOBE NEWSWIRE) --
By Grabar Law Office · Via GlobeNewswire · January 9, 2026
PHILADELPHIA, Jan. 08, 2026 (GLOBE NEWSWIRE) --
By Grabar Law Office · Via GlobeNewswire · January 8, 2026
PHILADELPHIA, Jan. 07, 2026 (GLOBE NEWSWIRE) --
By Grabar Law Office · Via GlobeNewswire · January 7, 2026
By Grabar Law Office · Via GlobeNewswire · January 5, 2026
PHILADELPHIA, Jan. 02, 2026 (GLOBE NEWSWIRE) --
By Grabar Law Office · Via GlobeNewswire · January 2, 2026
PHILADELPHIA, Dec. 31, 2025 (GLOBE NEWSWIRE) --
By Grabar Law Office · Via GlobeNewswire · December 31, 2025
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Lifecore Biomedical, Inc. (NASDAQ: LFCR) breached their fiduciary duties to shareholders.
By Halper Sadeh LLC · Via Business Wire · December 7, 2025
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In LifeCore (LFCR) To Contact Him Directly To Discuss Their Options
By Bragar Eagel & Squire · Via GlobeNewswire · September 27, 2025
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In LifeCore (LFCR) To Contact Him Directly To Discuss Their Options
By Bragar Eagel & Squire · Via GlobeNewswire · August 14, 2025
-- Recorded Revenues of $35.2 Million for Q3 Fiscal 2025 --
By Lifecore Biomedical, Inc. · Via GlobeNewswire · April 3, 2025

Company Seeking to Remove Convertible Preferred Stock Exchange Cap to Permit Potential Conversion of Series A Preferred Stock as Contemplated by the Series A Preferred Stock Terms
By Lifecore Biomedical, Inc. · Via GlobeNewswire · January 17, 2025

Company Believes it is Well Positioned for Mid-Term and Long-Term Growth asCurrent Capacity Continues to Support up to $300 Million in Annual Revenue
By Lifecore Biomedical, Inc. · Via GlobeNewswire · January 7, 2025

CHASKA, Minn., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 43rd Annual J.P. Morgan Healthcare Conference. The conference will take place January 13-16, 2025, in San Francisco, California.
By Lifecore Biomedical, Inc. · Via GlobeNewswire · January 6, 2025

-- Recorded Revenues of $32.6 Million for Q2 Fiscal 2025 --
By Lifecore Biomedical, Inc. · Via GlobeNewswire · January 2, 2025

Webcast Scheduled for Thursday, January 2 at 4:30 p.m. Eastern
By Lifecore Biomedical, Inc. · Via GlobeNewswire · December 19, 2024

Development Services Span Tech Transfer, Process Assessment and Method Validation for Fill and Finish of NRS-033 for Planned Phase 2 Trial
By Lifecore Biomedical, Inc. · Via GlobeNewswire · December 19, 2024

Three-Year Term Extension Combined with Simplification and Reduction of Interest Rates Helps Further Strengthen Company’s Balance Sheet and Overall Financial Position
By Lifecore Biomedical, Inc. · Via GlobeNewswire · November 26, 2024
